Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11657554 | 1.00 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL11657559 | 1.00 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL11657849 | 0.98 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL11657859 | 0.98 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL29630333 | 0.95 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL16777806 | 0.93 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL29590439 | 0.90 | OPRD1 (0.37) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL11656504 | 0.90 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL11656501 | 0.90 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL7746270 | 0.89 | PTGS1 (0.39) | ALDH1A1LMNAMAPTPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139248-A1 | DIRECT REPROGRAMMING OF HUMAN ASTROCYTES TO NEURONS WITH CRISPR-BASED TRANSCRIPTIONAL ACTIVATION | DUKE UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705462-A2 | COMPOSITIONS AND METHODS FOR ENGINEERING MATURE IPSC-DERIVED AND ESC-DERIVED HEPATOCYTES | Duke University (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250262326-A1 | EFFECTOR DOMAINS FOR CRISPR-CAS SYSTEMS | DUKE UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| EP-4590323-A2 | DIRECT REPROGRAMMING OF HUMAN ASTROCYTES TO NEURONS WITH CRISPR-BASED TRANSCRIPTIONAL ACTIVATION | Duke University (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250197823-A1 | COMPOSITIONS AND METHODS FOR EPIGENOME EDITING TO ENHANCE T CELL THERAPY | DUKE UNIVERSITY | 2025-06-19 | — | — | US | disclosed |
| US-20250171754-A1 | CRISPR-CAS9 COMPOSITIONS AND METHODS WITH A NOVEL CAS9 PROTEIN FOR GENOME EDITING AND GENE REGULATION | NORTH CAROLINA STATE UNIVERSITY | 2025-05-29 | — | — | US | disclosed |
| WO-2025049903-A2 | NOVEL REGULATORS OF T CELLS | DUKE UNIVERSITY (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025038982-A2 | REGULATORS OF T CELL EXHAUSTION | DUKE UNIVERSITY (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4508096-A2 | EFFECTOR DOMAINS FOR CRISPR-CAS SYSTEMS | Duke University (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4482955-A2 | CRISPR-CAS9 COMPOSITIONS AND METHODS WITH A NOVEL CAS9 PROTEIN FOR GENOME EDITING AND GENE REGULATION | Duke University (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20230257723-A1 | CRISPR/CAS9 THERAPIES FOR CORRECTING DUCHENNE MUSCULAR DYSTROPHY BY TARGETED GENOMIC INTEGRATION | DUKE UNIVERSITY | 2023-08-17 | — | — | US | disclosed |
| US-20230159927-A1 | CHROMATIN REMODELERS TO ENHANCE TARGETED GENE ACTIVATION | UNIV DUKE (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4126224-A1 | A HIGH-THROUGHPUT SCREENING METHOD TO DISCOVER OPTIMAL GRNA PAIRS FOR CRISPR-MEDIATED EXON DELETION | Duke University (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4127179-A2 | CHROMATIN REMODELERS TO ENHANCE TARGETED GENE ACTIVATION | Duke University (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126073-A1 | CRISPR/CAS9 THERAPIES FOR CORRECTING DUCHENNE MUSCULAR DYSTROPHY BY TARGETED GENOMIC INTEGRATION | Duke University (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023010135-A1 | COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF METHYL-CPG BINDING PROTEIN 2 (MECP2) | TUNE THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023010133-A2 | COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF FRATAXIN (FXN) | TUNE THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022187288-A2 | SYSTEMS AND METHODS FOR GENOME-WIDE ANNOTATION OF GENE REGULATORY ELEMENTS LINKED TO CELL FITNESS | DUKE UNIVERSITY (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022104159-A1 | TARGETED GENE REGULATION OF HUMAN IMMUNE CELLS WITH CRISPR-CAS SYSTEMS | DUKE UNIVERSITY (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022087321-A1 | DUAL AAV VECTOR-MEDIATED DELETION OF LARGE MUTATIONAL HOTSPOT FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | DUKE UNIVERSITY (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139248-A1 | DIRECT REPROGRAMMING OF HUMAN ASTROCYTES TO NEURONS WITH CRISPR-BASED TRANSCRIPTIONAL ACTIVATION | NR4A2, POU2F2, NR2F2 | ALDH1A1 3435/4885LMNA 1903/4885MAPT 1280/4885 |
| US-20250262326-A1 | EFFECTOR DOMAINS FOR CRISPR-CAS SYSTEMS | CALCOCO2, ZFX, DCAF7 | ALDH1A1 4870/4885LMNA 3103/4885MAPT 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.